Merck, Pfizer Sue Mylan Over Generic Eye Drug Application

Law360, Washington (June 17, 2013, 6:25 PM EDT) -- Pfizer Inc., Merck Sharp & Dohme Corp. and InSite Vision Inc. banded together Monday to slam Mylan Pharmaceuticals Inc. with an infringement suit in New Jersey federal court, alleging Mylan's application to market a generic version of the eye drug AzaSite violates four of their patents.

Mylan informed the companies about May 1 that it had filed an abbreviated new drug application with the U.S. Food and Drug Administration to market a generic version of the AzaSite azithromycin eye drops, which are used as a bacterial conjunctivitis treatment. Although Mylan maintained its product wouldn't infringe on the patents-in-suit in its Paragraph...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!